If your team is still rebuilding the competitive picture by hand before every launch readiness review or board update, that’s a data engineering gap, not an analyst gap. Perceptive Analytics builds the pipeline that reconciles SEC filings, trial registries, and patent data against your own Veeva and IQVIA data, so the answer to “where do we actually stand” is one query, not one more all-nighter.
The Question Your CEO Actually Asks
Not “what’s our competitor doing.” It’s “are we behind, how bad is it, and what would it take to catch up,” usually asked forty-eight hours before a board meeting.
Your team can answer it. It just takes the analyst three days of manually cross-checking ClinicalTrials.gov against last quarter’s 10-Q against a conference abstract someone forwarded on Slack, because none of those three sources were built to talk to each other, and none of them talk to your own Veeva CRM or IQVIA claims data either.
Perceptive Analytics builds the pipeline that closes that gap permanently, not just for this board meeting.
Where the Real Signal Already Lives
Your commercial team already has Veeva, IQVIA, and Symphony Health data on your own performance. The missing half is the same categories of data, public, for every competitor:
- Trial registry status changes (phase shifts, endpoint changes, enrollment pace) that move faster than any analyst newsletter
- SEC filings where R&D spend by program and forward-looking risk language shift months before any press release
- Orange Book and patent listings that tell you, years out, exactly when a competitor’s exclusivity actually ends
None of this requires a new subscription. It requires connecting these public sources to the Veeva and IQVIA data you already pay for, which is exactly what Perceptive Analytics builds inside its Life Sciences Commercial Analytics practice.
Why This Always Ends Up as a Data Engineering Problem
The same molecule shows up under a different name in every source your team pulls from: a generic name in a patent filing, a brand name on an earnings call, an NCT number in the trial registry, and yet another internal program code in your own Veeva instance.
Matching those identifiers to each other is the actual work. It’s not a research task an analyst does faster with more coffee, it’s an entity-resolution problem a pipeline solves once and keeps solving automatically. Perceptive Analytics builds that matching logic specifically around your competitor set and your own systems, not a generic industry-wide database that doesn’t know your product codes.
What a Working Pipeline Actually Looks Like
- Pulls trial phase, status, and endpoint changes directly from the registry the day they post
- Tracks Orange Book and patent exclusivity dates against your own launch timeline automatically
- Flags R&D spend and pipeline language shifts in competitor SEC filings as they’re filed
- Matches every one of those signals back to the same molecule, no matter what name each source uses
- Surfaces changes inside the same environment your team already uses, not a separate tool nobody opens
Build, Buy, or Partner
Enterprise platforms like Clarivate’s Cortellis, Norstella’s Citeline, and IQVIA, along with boutique strategy firms like Trinity Life Sciences, cover this territory at enterprise scale and enterprise pricing. If you need a pipeline built specifically around your own competitor set and your own Veeva or IQVIA instance, that scale is often more than the problem calls for.
Requirement | Enterprise CI Platform/Firm | Perceptive Analytics |
Broad, subscription-based industry database | Strong fit | Not the primary use case |
Pipeline matched to your specific competitors and systems | Limited to the platform’s own logic | Strong fit |
Connected directly to your own Veeva or IQVIA data | Usually a separate integration project | Built in from the start |
Mid-market budget and timeline | Enterprise subscription pricing | Built around mid-market scope |
Key Takeaways
- The data your CI team needs is already public. The gap is a pipeline that connects it to your own Veeva and IQVIA systems, not another subscription.
- The real bottleneck is entity resolution: matching the same molecule across a patent filing, an earnings call, and a trial registry.
- A pipeline scoped to one therapeutic area or competitor set can be live in weeks.
- Perceptive Analytics builds this pipeline specifically around your systems, not a generic industry-wide platform.
Stop Rebuilding the Same Analysis Every Quarter
If your team is still manually reconciling ClinicalTrials.gov, SEC filings, and your own Veeva data before every board update, that’s exactly what Perceptive Analytics builds a pipeline to fix, permanently.
Book a free pharma CI pipeline assessment with Perceptive Analytics. Visit our Life Sciences Commercial Analytics page to get started.
Frequently Asked Questions
Is this legal? It's a lot of competitor data.
Every source involved, SEC filings, ClinicalTrials.gov, the FDA Orange Book, is a public government record built for exactly this kind of use. There’s no gray area here.
Do we need to drop our current CI subscription to do this?
No. This runs alongside whatever platform you already have. Most of the value comes from connecting public data to your own Veeva or IQVIA instance, which a generic platform subscription doesn’t do for you.
How fast can this actually get built?
Scoped to a single therapeutic area or a defined competitor set, this is a matter of weeks, not a multi-quarter platform rollout.
What's the single biggest thing this fixes?
The three days someone loses before every board or launch readiness meeting, manually reconciling sources that should already talk to each other.